EXPERT INSIGHTS
A media library featuring your peers discussing clinical data and their clinical experience in prescribing RINVOQ.1
GUT REACTIONS PODCAST
Gut Reactions brings in-depth conversations, professional insights, and experience to your podcast rotation. Tune in, as leading gastroenterologists gather for one-on-one conversations with host, David Rubin, MD.
DR. RUBIN
Dr. Rubin is a professor and practitioner of medicine, Chief, Section of Gastroenterology, Hepatology and Nutrition and Co-Director of the Digestive Disease Center at the University of Chicago. He is a renowned gastroenterologist specializing in the assessment and treatment of digestive diseases including IBD (Crohn’s disease and ulcerative colitis). Gut Reactions will feature his discussions around the evolving treatment landscape, a treatment option, and patient outcomes.
In this episode, Oriana M. Damas, MD, MSCTI joins Dr. Rubin for a discussion on the importance of objective measures in UC—such as endoscopic improvement and histo-endoscopic mucosal improvement—and how they fit into your clinical practice.
The discussion will also include an exploration of RINVOQ (upadacitinib) data demonstrating endoscopic improvement of the colon.
A loss of response does not mean a loss of getting UC under control. Dr. Rubin brings Josh Steinberg, MD to the table to discuss the evaluation of primary and secondary loss of response, and identifying moderate to severe UC patients that are inadequately responding to a TNFi who may need a treatment change.
From there, they share their personal experience with switching patients to RINVOQ (upadacitinib).
RINVOQ REELS: Gastro Edition
A video library featuring your peers discussing clinical data and sharing opinions about treating moderate to severe UC.
